This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo

Ticker(s): INCY

Who's the expert?

Institution: Oregon Medical Research Center

  • Board Certified Dermatologist and President of Oregon Medical Research Center.
  • Laboratory published key papers on the role of IL-23/Th17 biology in psoriasis.
  • PI on multiple trials with emphasis on psoriasis including including PSTELLAR, FEATURE, IXORA-R, VOYAGE 1, IMMhance, CHRONOS, ECZTEND, JADE REGIMEN, and HEADS UP.
  • Research and clinical expertise has been in Langerhans cell biology, T cell immunology, virology, psoriasis, and atopic dermatitis; published over 300 peer reviewed papers.

Interview Questions

Roughly how many patients do you currently manage with non-segmental vitiligo?

Added By: dami_admin

Have you prescribed Ruxolitinib? Rough number of patients?

Added By: dami_admin

On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Opzelura as a treatment for vitiligo

Added By: dami_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.